At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
PF-07265803drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, OPEN-LABEL, SINGLE-PERIOD, NON-RANDOMIZED STUDY TO EVALUATE THE PHARMACOKINETICS, EXCRETION, MASS BALANCE AND METABOLISM OF [14C]PF-07265803 ADMINISTERED ORALLY TO HEALTHY ADULT MALE PARTICIPANTS
In Brief
A Phase 1 clinical trial evaluating PF-07265803 for Healthy. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the pharmacokinetics, excretion, mass balance and metabolism of PF-07265803 (formerly known as ARRY-371797) in approximately 6 healthy adult male participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartMar 2022
Primary CompletionMay 2022
TodayJul 2026
First PostedMar 18, 2022
Enrollment StartMar 31, 2022
Primary CompletionMay 26, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.3 years ago
Interventions
PF-07265803drug
PF-07265803 is a p38 inhibitor formulated for oral delivery.